

# ***N*-[1-(2-Chlorophenyl)-2-{1-methyl-5-nitro-4-[(phenylsulfonyl)methyl]-1*H*-imidazol-2-yl}ethyl]-4-methylbenzenesulfonamide**

Romain Paoli-Lombardo <sup>1</sup>, Nicolas Primas <sup>1,2,\*</sup>, Caroline Castera-Ducros <sup>1,2</sup>, Inès Jacquet <sup>1</sup>, Pascal Rathelot <sup>1,2</sup> and Patrice Vanelle <sup>1,2,\*</sup>

<sup>1</sup> CNRS, ICR UMR 7273, Team Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Aix Marseille University, 27 Boulevard Jean Moulin, CS30064, CEDEX 05, 13385 Marseille, France

<sup>2</sup> Service Central de la Qualité et de l'Information Pharmaceutiques, Hôpital de la Conception, AP-HM, 13005 Marseille, France

\* Correspondence: nicolas.primas@univ-amu.fr (N.P.); patrice.vanelle@univ-amu.fr (P.V.)

## **Supplementary materials**

**Figure S1:** <sup>1</sup>H NMR spectrum of compound **3**.

**Figure S2:** <sup>13</sup>C NMR spectrum of compound **3**.

Figure S1: <sup>1</sup>H NMR spectrum of compound 3.




Figure S2:  $^{13}\text{C}$  NMR spectrum of compound 3.

